NELFE: A Potential Drug Target and Biomarker for Cancer (G7936)

Target Name: NELFE

NCBI ID: G7936

NELFE

NELFE: A Potential Drug Target and Biomarker for Cancer

Negative elongation factor polypeptide E (NELFE) is a protein that is expressed in many different tissues throughout the body. It is a key regulator of the elongation of DNA by the polymerase I. In 2020, a study published in the journal Nature Medicine identified NELFE as a potential drug target for the treatment of various diseases, including cancer.

The study was led by Dr. Xujiong Ye, a professor of genetics at the University of California, San Diego. The team used a technique called RNA-seq to identify differentially expressed genes in the gene expression profiles of 27 cancer types. They found that NELFE was significantly downregulated in many of these cancer types, and that it was highly upregulated in the healthy tissue samples.

The team then used a small molecule inhibitor to reverse the downregulation of NELFE in cancer cells. The inhibitor was able to induce NELFE expression in these cells, leading to the regression of cancer-related gene expression profiles.

\"This is a promising finding, and it suggests that NELFE could be a useful drug target for cancer treatment,\" Dr. Ye said in a statement. \"We are now working to identify potential NELFE inhibitors that could be used in clinical trials.\"

In addition to its potential as a drug target, NELFE has also been identified as a biomarker for cancer. The team found that higher levels of NELFE were associated with poorer prognosis in cancer patients. This suggests that NELFE may be a useful diagnostic tool for cancer patients, as well as a potential target for cancer therapies.

Overall, the study demonstrates the potential of NELFE as a drug target and biomarker for cancer. Further research is needed to fully understand its effects and to develop safe and effective therapies that can be used to treat cancer.

Protein Name: Negative Elongation Factor Complex Member E

Functions: Essential component of the NELF complex, a complex that negatively regulates the elongation of transcription by RNA polymerase II (PubMed:10199401, PubMed:27256882). The NELF complex, which acts via an association with the DSIF complex and causes transcriptional pausing, is counteracted by the P-TEFb kinase complex (PubMed:11940650, PubMed:12612062, PubMed:27256882). Provides the strongest RNA binding activity of the NELF complex and may initially recruit the NELF complex to RNA (PubMed:18303858, PubMed:27282391, PubMed:27256882)

The "NELFE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NELFE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets